Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 333-339

  Wu, Shang Gin ^a   Yang, Chih Hsin ^a   Yu, Chong Jen ^a   Lee, Jih Hsiang ^a   Hsu, Ya Chieh ^a   Chang, Yih Leong ^a   Shih, Jin Yuan ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adenocarcinoma; EGFR mutation; Lung cancer; Pemetrexed

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMOKING; TISSUE SECTION; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GLUTAMATES; GREEN FLUORESCENT PROTEINS; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING;

EID: 79955474006     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.012     Document Type: Article

References (49)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
3. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
4. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
5. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
6. Smit E.F., Mattson K., von Pawel J., Manegold C., Clarke S., Postmus P.E. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003, 14:455-460.
7. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase II trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
8. Zinner R.G., Fossella F.V., Gladish G.W., Glisson B.S., Blumenschein G.R., Papadimitrakopoulou V.A., et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005, 104:2449-2456.
9. Manegold C., Gatzemeier U., von Pawel J., Pirker R., Malayeri R., Blatter J., et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000, 11:435-440.
10. Shepherd F.A., Dancey J., Arnold A., Neville A., Rusthoven J., Johnson R.D., et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001, 92:595-600.
11. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
12. Peterson P., Park K., Fossella F. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007, 2(Suppl. 4):316-317.
13. Peng G., Zinner R.G., Wang Y., Treat J., Monberg M., Obasaju C.K., et al. Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials. J Clin Oncol 2008, 26(Suppl. 15):447s.
14. Ohe Y., Ichinose Y., Nakagawa K., Tamura T., Kubota K., Yamamoto N., et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4206-4212.
15. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
16. Davies R.L., Grosse V.A., Kucherlapati R., Bothwell M. Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. Proc Natl Acad Sci U S A 1980, 77:4188-4192.
17. Scagliotti G.V., Selvaggi G., Novello S., Hirsch F.R. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004, 10:4227s-4232s.
18. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
19. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
20. Ellis P.M., Morzycki W., Melosky B., Butts C., Hirsh V., Krasnoshtein F., et al. The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. Curr Oncol 2009, 16:27-48.
21. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
22. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246.
23. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
24. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
25. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005, 65:226-235.
26. de Marinis F., Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008, 13(Suppl. 1):14-20.
27. Travis W.D.B.E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics of tumors of the lung, pleura, thymus and heart 2004, 9-122. IARC Press, Lyon.
28. Eisenhauer E.A, Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
29. Shih J.Y., Gow C.H., Yu C.J., Yang C.H., Chang Y.L., Tsai M.F., et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006, 118:963-969.
30. Wu J.Y., Yu C.J., Yang C.H., Wu S.G., Chiu Y.H., Gow C.H., et al. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med 2008, 178:847-853.
31. Wu S.G., Gow C.H., Yu C.J., Chang Y.L., Yang C.H., Hsu Y.C., et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008, 32:924-930.
32. Smit E.F., Burgers S.A., Biesma B., Smit H.J., Eppinga P., Dingemans A.M., et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:2038-2045.
33. Lee K.H., Han S.W., Hwang P.G., Oh D.Y., Kim D.W., Chung D.H., et al. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. Jpn J Clin Oncol 2006, 36:344-350.
34. Giovannetti E., Mey V., Nannizzi S., Pasqualetti G., Marini L., Del Tacca M., et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005, 68:110-118.
35. Sigmond J., Backus H.H., Wouters D., Temmink O.H., Jansen G., Peters G.J. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003, 66:431-438.
36. Gomez H.L., Santillana S.L., Vallejos C.S., Velarde R., Sanchez J., Wang X., et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006, 12:832-838.
37. Bepler G., Sommers K.E., Cantor A., Li X., Sharma A., Williams C., et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008, 3:1112-1118.
38. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
39. Giovannetti E., Lemos C., Tekle C., Smid K., Nannizzi S., Rodriguez J.A., et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008, 73:1290-1300.
40. Magne N., Fischel J.L., Dubreuil A., Formento P., Ciccolini J., Formento J.L., et al. (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003, 9:4735-4742.
41. Budman D.R., Soong R., Calabro A., Tai J., Diasio R. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Anticancer Drugs 2006, 17:921-928.
42. Matsumoto S., Igishi T., Hashimoto K., Kodani M., Shigeoka Y., Nakanishi H., et al. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer. Int J Oncol 2004, 25:1311-1318.
43. van der Wilt C.L., van Laar J.A., Gyergyay F., Smid K., Peters G.J. Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. Eur J Cancer 1992, 28A:2017-2024.
44. Guichard S., Hennebelle I., Bugat R., Canal P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998, 55:667-676.
45. Yang C.H., Simms L., Park K., Lee J.S., Scagliotti G., Orlando M. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol 2010, 5:688-695.
46. Yang S.P., Luh K.T., Kuo S.H., Lin C.C. Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration-a 30-year consecutive study. Jpn J Clin Oncol 1984, 14:7-19.
47. Luh K.T., Chang D.B. Primary lung cancer in Taiwan. J Formos Med Assoc 1992, 91(Suppl. 1):S1-7.
48. Wu S.G., Chang Y.L., Hsu Y.C., Wu J.Y., Yang C.H., Yu C.J., et al. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist 2008, 13:1276-1284.
49. Wu J.Y., Wu S.G., Yang C.H., Gow C.H., Chang Y.L., Yu C.J., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008, 14:4877-4882.